Naphazoline: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Naphazoline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(No difference)

Revision as of 19:33, 27 September 2011

Naphazoline
Clinical data
Routes of
administration
Topical
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H14N2
Molar mass210.274

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Naphazoline (in the hydrochloride form) is the common name for 2-(1-Naphthylmethyl)-2-imidazoline hydrochloride, It is a sympathomimetic agent with marked alpha adrenergic activity. It is a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane. It acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion. It is an active ingredient in Naphcon-A and Clearine eye drops. It has the molecular formula C14H14N2.HCl and a molecular weight of 246.73 g/mol.

Warnings and contraindications

These apply to all naphazoline-containing substances intended for medicinal use. A few warnings and contraindications are:-

1.Hypersensitivity to Naphazoline.
2.Patients taking MAO inhibitors can experience a severe hypertensive (see hypertension) crisis if given a sympathomimetic drug such as naphazoline HCl.
3.Use in infants and children can result in CNS depression, leading to coma and marked reduction in body temperature.
4.Should be used with caution in patients with severe cardiovascular disease including cardiac arrythmia and in patients with diabetes, especially those with a tendency toward diabetic ketoacidosis.
5 Drug interactions can occur with anaesthetics that sensitize the myocardium to sympathomimetics (e.g cyclopropane or halothane cautiously.
6.Exercise caution when applying prior to use of phenylephrine.


Template:SIB

Template:WH

Template:WikiDoc Sources